BioMed Central | Articles which cite: HER2 therapy: molecular mechanisms of trastuzumab resistance.

home journals A-Z subject areas advanced search authors reviewers libraries about my BioMed Central

printer friendly

to [Help]

PubMed Central articles that cite the above article:

1.	Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Amit I, Wides R, Yarden Y Mol Syst Biol 2007, 3:151 [PubMed Central] [PubMed] [Related articles]
2.	Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA PLoS One 2009, 4:e6251 [PubMed Central] [PubMed] [Related articles]
3.	HER2 breast cancer therapies: a review. Murphy CG, Modi S Biologics 2009, 3:289-301 [PubMed Central] [PubMed] [Related articles]
4.	A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Raja SM, Clubb RJ, Bhattacharyya M, Dimri M, Cheng H, Pan W, Ortega-Cava C, Lakku-Reddi A, Naramura M, Band V, Band H Cancer Biol Ther 2008 Oct, 7:1630-40 [PubMed Central] [PubMed] [Related articles]
5.	IGF-1 receptor inhibitors in clinical trials--early lessons. Weroha SJ, Haluska P J Mammary Gland Biol Neoplasia 2008 Dec, 13:471-83 [PubMed Central] [PubMed] [Related articles]

This article is also cited by 6 articles in BioMed Central

You can also check ISI Web of Science for additional citations (subscription required)

printer friendly

to [Help]